Open Label Phase II Randomized Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or in Combination With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced GIST That Have Progressed on High Dose Imatinib.
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Imatinib; Nilotinib
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 08 Mar 2012 Planned end date changed from 1 Feb 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 08 Mar 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.